Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Supplement Articles

Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance

Rachel Schiff, Suleiman A. Massarweh, Jiang Shou, Lavina Bharwani, Syed K. Mohsin and C. Kent Osborne
Rachel Schiff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suleiman A. Massarweh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiang Shou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lavina Bharwani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syed K. Mohsin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Kent Osborne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-031212 Published January 2004
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Estrogen receptor (ER) and growth factor (GF) pathway cross-talk in endocrine resistance: a working model. The ligand estrogen (E) induces genomic-nuclear (N) ER activity, which results in increased gene transcription, including important genes in the growth factor pathways. Estrogen deprivation (−E2), the antiestrogen tamoxifen (T), and the potent antiestrogen fulvestrant (F) antagonize this activity. However, both estrogen and tamoxifen can turn on nongenomic membrane (M) and/or cytoplasmic (C) ER, which, in turn, through multiple interactions with signaling intermediate molecules (SIM; see text), can activate tyrosine kinase receptors (TKR) and cellular kinase cascades. Subsequent phosphorylation (P) of the ER and its coactivators (CoA) and corepressors (CoR) by these kinases (e.g., ERK/MAPK and AKT) then potentiates the genomic-nuclear ER activity. Increased GF signaling (by overexpression of GFs or TKRs) augments both activities of the ER and can result in endocrine resistance to antiestrogens like tamoxifen. This cycle can possibly be broken either by inhibitors of the GF/TKR pathways [TKIs or antibody (Ab) -based], which restore sensitivity to tamoxifen, or by abolition of the ER pathway by ligand deprivation or by ER degradation using fulvestrant (ERE, promoters containing diverse ER-responsive elements.)

PreviousNext
Back to top
Clinical Cancer Research: 10 (1)
January 2004
Volume 10, Issue 1
  • Table of Contents
  • About the Cover
  • Index by Author

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
Rachel Schiff, Suleiman A. Massarweh, Jiang Shou, Lavina Bharwani, Syed K. Mohsin and C. Kent Osborne
Clin Cancer Res January 1 2004 (10) (1) 331s-336s; DOI: 10.1158/1078-0432.CCR-031212

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
Rachel Schiff, Suleiman A. Massarweh, Jiang Shou, Lavina Bharwani, Syed K. Mohsin and C. Kent Osborne
Clin Cancer Res January 1 2004 (10) (1) 331s-336s; DOI: 10.1158/1078-0432.CCR-031212
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Open Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Supplement Articles

  • Malignant Mammary Cells Acquire Independence from Extracellular Context for Regulation of Estrogen Receptor α
  • Adaptive Hypersensitivity to Estrogen
  • Nonendocrine Pathways and Endocrine Resistance
Show more 3

Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer

  • Malignant Mammary Cells Acquire Independence from Extracellular Context for Regulation of Estrogen Receptor α
  • Adaptive Hypersensitivity to Estrogen
  • Nonendocrine Pathways and Endocrine Resistance
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement